ORKA
Research Snapshot
Static fundamentals, valuation context, and investor signals for Oruka Therapeutics, Inc. (ORKA).
DCF ready
Valuation
N/A
EV/FCF, N/A FCF yield
Quality
-22.3%
ROIC, N/A FCF margin
Growth
N/A
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 22.4x current ratio
Superinvestors
1
Top: Viking Global Investors (0.4%)
Strengths to research
- Debt/equity looks manageable at 0.0x.
- 10 annual periods are available for trend analysis.
Watchouts
- Valuation multiples are limited or unavailable.
Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for ORKA.
Grade F
2
/ 100
Financial Charts
No financial data available for ORKA (annual).
1 superinvestors own ORKA
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Viking Global Investors Viking Global Investors | 2,666,690 | $131M | 0.37% | 0.0% |